Alzamend Neuro
ALZN
9 hedge funds and large institutions have $71.2K invested in Alzamend Neuro in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.07% more ownership
Funds ownership: 0.05% → 0.12% (+0.07%)
31% less funds holding
Funds holding: 13 → 9 (-4)
53% less capital invested
Capital invested by funds: $150K → $71.2K (-$79.3K)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$48.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.6K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$2.9K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$288 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$31K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$21.2K |
| 3 |
Renaissance Technologies
New York
|
-$7.77K |
| 4 |
RA
RFG Advisory
Birmingham,
Alabama
|
-$6.57K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.02K |
ALZN Hedge Fund Activity: Q3 2024 in Review
9 of the 6,967 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q3 2024, worth a combined $71.2K — down 53% from $150K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ALZN and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $48.3K. The largest seller was Vanguard Group, exiting entirely with an estimated $31K sold.
- 9 institutional investors held Alzamend Neuro (ALZN) as of Q3 2024, down from 13 in Q2 2024.
- Funds reported $71.2K of Alzamend Neuro stock for Q3 2024, down 53% quarter-over-quarter.
- 2 funds opened new Alzamend Neuro positions in Q3 2024 and 6 closed out, a net change of -4 holders.
- The largest Alzamend Neuro buyer in Q3 2024 was Susquehanna International Group, an estimated $48.3K added.
- The largest Alzamend Neuro seller in Q3 2024 was Vanguard Group, an estimated $31K sold.
Based on aggregated 13F filings for Q3 2024.